Rodell, Timothy C.

Mutation-selective tumor remission with Ras-targeted, whole yeast-based immunotherapy

Lu, Y., Bellgrau, D., Dwyer-Nield, L. D., Malkinson, A. M., Duke, R. C., Rodell, T. C., & Franzusoff, A. (2004) · Cancer Research

Immunotherapy and Immune ResponsesCancer Immunotherapy and Biomarkers

Cited by 71

Whole recombinant Saccharomyces cerevisiae yeast expressing Ras mutations as treatment for patients with solid tumors bearing Ras mutations: Results from a phase 1 trial

Cohn, A., Morse, M. A., O’Neil, B., Whiting, S., Coeshott, C., Ferraro, J., Bellgrau, D., Apelian, D., & Rodell, T. C. (2018) · Journal of Immunotherapy

Immunotherapy and Immune ResponsesBacterial Cancer Therapy

Cited by 41

A Phase 2 Randomized Placebo-Controlled Adjuvant Trial of GI-4000, a Recombinant Yeast Expressing Mutated RAS Proteins in Patients with Resected Pancreas Cancer

Muscarella, P., Bekaii-Saab, T., McIntyre, K., Rosemurgy, A., Ross, S. B., Richards, D. A., Fisher, W. E., Flynn, P. J., Mattson, A., Coeshott, C., et al. (2021) · Journal of Pancreatic Cancer

Pancreatic and Hepatic Oncology ResearchImmunotherapy and Immune Responses

Cited by 24